By Josh White
Date: Tuesday 25 Jun 2024
(Sharecast News) - Shares of German chemical and pharmaceutical firm Merck were falling sharply on Tuesday, after it announced that a trial for its head and neck cancer drug xevinapant had been halted due to a lack of efficacy.
The development was the latest in a series of significant setbacks for...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news